Galectins comprise a relatively large family of carbohydrate-binding proteins that recognize and bind to β-D-galactoside residues expressed on a variety of different molecules. Advances in the study of their biological activities demonstrate potential functions in cancer progression, inflammatory, immune, and fibrotic responses which have recently translated to target the galectins as novel therapeutic strategies to address unmet medical needs. This review will summarize the therapeutic applications of galectin antagonists to treat human diseases currently in clinical trials.
A. Introduction
The β-galactoside-binding lectins are widely expressed in many different species including primitive organisms such as the slime mold, Dictyostelium discoidin, described in 1975 as discoidin (1) . The search for the presence of similar β-galactoside-binding proteins in vertebrates led to the discovery of "electrolectin" extracted from the electric eel (2) and galectins from mammalian tissues of calf heart (3) and chicken organs (4) . Studies to characterize the binding epitopes of electrolectin led to the early discovery of thiodigalactoside (TDG) as a strong commercially available antagonist. TDG has since been used as a lead structure for the rational design of potent small molecule glycomimetic antagonists of the galectins now in clinical trials (5) . Currently, 15 different galectins have been described in mammals and 11 of them are found in humans. All of these galectins share a common sequence motif of about 130 amino acids known as the carbohydrate-recognition domain (CRD). While the binding motifs share similarities, slight differences of precise epitopes among the galectins have been identified and can be used to design antagonists with increased specificity for particular galectins in this family (6, 7) .
The galectin family can be divided into 3 subgroups depend- (Article for special issue on Galectins) SE212 with CRD's expressed in the C terminus that may be linked together by the N-terminal domain. Of these members, galectin-5, 6, 11 and 15 are not found in humans.
A common feature among these subgroups is the ability to form multivalent interactions with expressed galactoside ligands on cell surfaces. The biological activities of the galectins are consistent with the effects of multivalent interactions with target cells and may explain the molecular mechanisms of the galectins (Fig.   1 ). Some examples are the requirement of multivalent interactions to induce activation of pathways, such as the NFkB pathway in tumor cells inducing chemoresistance, the signaling interactions of galectin-9 and 3 with T-cell checkpoint inhibitors TIM-3 and LAG-3 to inhibit T-cell cytotoxicity for tumor cells (8, 9) and finally the multivalent lattice formation of galactosylated pro-collagen molecules to induce and promote fibrosis (10) . Galectin antagonists such as highly potent univalent small molecule glycomimetics that can block the formation of galectin-mediated multivalent interactions would be expected to have an advantage on the biological impact on these disease-associated mechanisms.
B. Indications for Clinical Applications B-1. Cancer
Aberrant glycosylation is one of the hallmarks of oncogenic transformation. The increased expression of galectins has also been reported in a wide variety of cancers such as colorectal (11) , lung (12), breast (13) , pancreatic (14) , and liver (15) and hematological malignancies (16) . The interactions of galectins with their carbohydrate ligands in cancer have been reported to promote these malignancies through mechanisms of inducing angiogenesis, metastasis, the apoptosis of immune cells, activation of chemoresistance pathways and immunosuppression of cytotoxic T-cells through checkpoint inhibition.
The production of new blood vessels in the tumor microenvironment, a process known as angiogenesis, is induced by the activation of the vascular endothelial growth factor receptor (VEGFR) by vascular endothelial growth factor (VEGF) and is known to promote tumor growth and metastasis (17) . VEGF is a validated target for cancer therapy and the approved drug, Bevacizumab is an anti-VEGF antibody that blocks interactions with VEGFR. Interestingly, galectin-1 has been shown to bind carbohydrates expressed on VEGFR and can activate it and stimulate angiogenesis in the absence of VEGF (18) .
Metastatic spread of cancer cells throughout the bloodstream to distal sites proceeds by binding to the vascular endothelium followed by extravasation and infiltration to target tissues. A common tumor-associated glycosylation alteration is the expression of a short galactose terminating carbohydrate known as the ThomsenFriedenreich (TF) antigen. Galectin-3 binds the TF antigen and is found at the endothelial surface with highly metastatic TF expressing breast cancer cells, but not a TF negative variant breast cancer cell line (19) . In addition, patients with metastatic disease express higher levels of circulating galectin-3 in comparison with patients with localized, primary tumors (20) . Galectin-2, 4 and 8 are also elevated in colon and breast cancer patients and function to accumulate and bind cancer cells to the endothelium as a first step in the metastatic process (21) .
Galectins also promote tumorigenesis by binding cancer cells and activating tumor survival pathways. Galectin-3 expression is greatly elevated in pancreatic tumor tissue and when bound to these cells will activate the AKT pathway thereby inducing a wellestablished chemoresistance in these cells (22) . In KRAS-mutant cancers (lung and pancreatic), galectin-3 has been reported to bind integrin αvβ3 and promote KRAS-mediated activation of AKT and associated chemoresistance (23, 24) . 
B-2. Cardiovascular Disease
Cardiovascular disease (CVD) is a silent killer and is a leading cause of death and disability worldwide. CVD progresses over time to cause cardiac remodeling associated with fibrosis and weakening of the cardiac tissues resulting in a condition known as heart failure (HF). After the diagnosis of HF, 60% of men and 45% of women will die within 5 years (25) . Early diagnosis is critical for successful therapeutic intervention, but is currently lacking and is a recognized unmet goal. It is now well established that galectin-3 functions in promoting fibrosis and is elevated during cardiac remodeling. In a large clinical study of 3,353 participants over 8 years (26) , the plasma level of galectin-3 was associated with the risk of incident HF with high statistical significance (p<0.0001).
This observation is supported in several other studies. In the Aldo- reported that elevated levels of galectin-3 are an independent predictor of adverse HF outcome (28) . In another study (29) of 599 subjects presenting in the emergency room with acute dyspnea, the circulating levels of galectin-3 were significantly higher among those dying within 60 days (p<0.001). The Deventer-Alkmaar Heart Failure (DEAL-HF) clinical study reported galectin-3 levels in patients with chronic HF were an independent predictor of mortality (30) . Using a multivariate model, the CARE-HF study showed the association of galectin-3 with elevated rates of death from HF. Even patients (n=592) with stable chronic heart failure, but with an ejection fraction of less than 35% (COACH study), galectin-3 was a prognostic marker of disease (31) . Based on the consistent and reproducible association of Galactin-3 levels and the progression of CVD among many studies, the use of galectin-3 as a biomarker in the Emergency Department to guide clinical decisions for the treatment of incoming patients has been proposed (32) . An automated commercial assay for galectin-3 to be used in a hospital setting has been developed by Abbott laboratories on their ARCHITECT system and has been approved for the prognosis of chronic heart failure (33) . Finally, as a biomarker, galectin-3 has been given a class II recommendation for the management of heart failure as stated in the ACCF/AHA guidelines (34).
While galectin-3 is acknowledged as a biomarker for cardiac fibrosis, pre-clinical studies have been advanced to determine whether it plays a functional role and can be considered a target for therapeutic intervention. Early studies using a homozygous transgenic rat model of hypertensive mediated heart failure (TGRmRen2-27 rats), identified galectin-3 as the most overexpressed 
B-3. Fibrotic Diseases
Fibrosis is a debilitating process of tissue scarring and injury to organs that leads to irreversible functional decline and eventual As determined by studies using both pre-clinical models and clinical samples, the expression of galectin-3 is consistent with the presence of fibrotic disease in a wide variety of tissues and organs. 
C. Galectin Antagonists
Many different strategies have been reported to target the galectins as antagonists in pre-clinical animal models. They include traditional small molecule drugs, antibodies and natural products.
This report will focus on the antagonists currently being tested in human clinical trials.
C-1. Small Molecule Drugs
These drugs typically range in size from molecular weight 500 to 1,000 and are selected to bind and inhibit the galectin target.
They are tradition drug-like compounds that are chemically synthesized and are highly characterized for purity, pharmacokinetics and toxicity. Strategies to discover these drugs range from large scale screening of galectin activity inhibition to rational design of a specific structure based on structure-activity relationships between the drug and its receptor on the galectin target. 
C-2. Antibodies
Antibody drugs can be highly specific and maintain a long (Table 1) . 
C-3. Natural Products

D. Clinical Trials
Nine (9) programs targeting the galectins or their associated ligands have been registered on www.clinicaltrials.gov (see Table   1 ). While these trials span a variety of indications, the majority of clinical trials are focused on fibrotic diseases and cancer indications.
GCS-100
GCS-100 is a complex polysaccharide that was prepared from 
DAVANAT (GM-CT-01)
DAVANAT is a polysaccharide, carbohydrate polymer, com- While a series of Phase II trials were planned in patients with cancer in the US and Europe, these trials were never initiated with status reported as "withdrawn/terminated" on www.clinicaltrials.
gov.
GR-MD-02
GR-MD-02 is a polysaccharide derived through chemical 
TD139
In contrast to plant-based complex compounds, Galecto Bio has taken a rational drug design approach and synthesized a highly potent, selective small-molecule antagonist of galectin-3 (TD139). (Table 1) to test these novel therapies. Some of these strategies will be more successful than others and as the galectins become validated pharmaceutical targets, opportunities for translational research for other carbohydrate binding proteins in the field of Glycobiology (i.e., siglecs, selectins, etc.) will advance and be recognized as a relatively untapped source of novel therapeutics for unmet medical needs.
